Christopher Anzalone, Arrowhead Pharmaceuticals CEO
February 15, 2023 11:13 AM ESTUpdated 11:48 AM
Deals
R&D

Up­dat­ed: J&J re­turns rights to ear­ly-stage, RNAi NASH can­di­date to Ar­row­head

Paul Schloesser

Associate Editor

J&J is hand­ing the rights to a Phase I NASH can­di­date, stem­ming from a 2018 multi­bil­lion-dol­lar deal, back to its de­vel­op­er.

Ar­row­head Phar­ma­ceu­ti­cals

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times